第八版AJCC TNM分期系统在食管鳞状细胞癌患者中的应用
本研究利用台湾癌症登记数据库,纳入接受食管切除术的c I-III期食管鳞状细胞癌患者,分别对c、p、yp分期进行生存分析,共纳入c分期3399例、p分期1805例、yp分期1594例。结果显示新分期系统具有良好的判别能力和梯度单调性,但yp I期患者异质性明显,作者建议未来将yp I期细分为ypT0N0与非ypT0N0。
要点
- c I、II、III期3年总生存率分别为67.4%、46.7%、38.4%。
- p I、II、III、IV期3年总生存率分别为70.7%、49.8%、30.8%、10.6%。
- yp I期患者异质性明显,作者建议未来细分为ypT0N0与非ypT0N0。
核心结论
- 本研究对第八版AJCC TNM分期系统在食管鳞状细胞癌患者预后判断中进行了外部验证,结果提示该系统具有稳健的判别能力和梯度单调性,但yp I期患者异质性明显,作者建议未来将yp I期细分为ypT0N0与非ypT0N0。
研究设计与样本
- 数据来自台湾癌症登记数据库,纳入接受食管切除术的c I至III期食管鳞状细胞癌患者进行生存分析。
- c、p、yp分期分别纳入3399例、1805例、1594例患者。
主要发现
- c I、II、III期的3年总生存率分别为67.4%、46.7%、38.4%。
- p I、II、III、IV期的3年总生存率分别为70.7%、49.8%、30.8%、10.6%。
- yp I、II、III、IV期的3年总生存率分别为59.4%、37.8%、27.6%、3.7%。
- ypT0N0期患者的5年总生存率为52.1%,与p I期患者的54.5%相当。
- ypTis-2N0期患者的5年总生存率为39.1%,与p II期患者的40.1%相当。
局限性
- yp I期患者为异质性明显的群体,生存差异较大,作者建议未来将其细分为ypT0N0与非ypT0N0。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The eighth edition of the American Joint Committee on Cancer Tumor-Node-Metastasis staging system separates classifications for the clinical (c), pathologic (p), and postneoadjuvant pathologic (yp) stages. We aimed to evaluate its application in patients with esophageal squamous cell carcinoma (ESCC). METHODS: Patient data were obtained from the Taiwan Cancer Registry database. Patients who underwent esophagectomy for c stage I to III ESCC were included for survival analysis. RESULTS: Data of 3,399, 1,805, and 1,594 patients were included for c, p, and yp staging, respectively. The 3-year overall survival (OS) rates for c stage I, II, and III were 67.4%, 46.7%, and 38.4%, respectively. The 3-year OS rates for p stage I, II, III, and IV were 70.7%, 49.8%, 30.8%, and 10.6%, respectively. The 3-year OS rates for yp stage I, II, III, and IV were 59.4%, 37.8%, 27.6%, and 3.7%, respectively. Survival curve analysis demonstrated a robust discriminatory capability and monotonicity of gradients of the new system. However, yp stage I was observed in a heterogeneous group of patients with substantial survival differences. Meanwhile, patients in the ypT0 N0 stage had a 5-year OS rate of 52.1%, which was equivalent to that of patients with p stage I (54.5%). The 5-year OS rate of patients in the ypTis-2N0 was 39.1%, which was equivalent to that of patients in p stage II (40.1%). CONCLUSIONS: The present study serves as an external validation of the newly released staging system in the prognostication of patients with ESCC and suggests subgrouping of the yp stage I into ypT0 N0 and non-ypT0 N0 in the future.
引用
- Hsu PK, Chen HS, Liu CC, et al. Application of the Eighth AJCC TNM Staging System in Patients With Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2018. PMID: 29409986. doi:10.1016/j.athoracsur.2017.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。